FENBENDAZOLE PROTOCOLS:
ACTIVE CANCER TREATMENT
For individuals undergoing active cancer treatment, the following regimen is suggested for potential supportive therapy:
Fenbendazole: Administer one capsule of 444mg daily. Some practitioners recommend taking a break once a week; for instance, you might consider not taking it on Sundays. Though there is no indication that you will develop a tolerance, occasional breaks can be beneficial.
CBD Oil: Enhance the protocol by applying 25mg (1-2 drops) under the tongue each night before bed to potentially induce a calming effect.
Curcumin: To bolster the regimen, consume 600mg twice daily with meals. Curcumin is known for its anti-inflammatory properties which can complement cancer treatments.
Milk Thistle: To support liver function, take 250mg twice daily with meals.
Note: Fenbendazole should be taken with food or after meals to promote optimal absorption.
COMPLEMENTARY CANCER TREATMENT
For comprehensive support alongside conventional cancer therapy:
Fenbendazole: Take one capsule of 222mg daily after a meal that contains fats.
CBD Oil: 25mg (1-2 drops) under the tongue each night before bedtime.
Curcumin: 600mg, twice daily after breakfast and lunch.
Note: Fenbendazole should be taken with food or after meals to promote optimal absorption.
CANCER RELAPSE PREVENTION
To reduce the risk of cancer relapse:
Fenbendazole: Consume one 222mg capsule three times a week, following a fatty meal.
CBD Oil: Apply 25mg under the tongue nightly.
Curcumin: Take 600mg, twice daily with meals.
Milk Thistle: To support liver function, take 250mg twice daily with meals.
Note: Regular monitoring of liver and kidney function by a healthcare professional is recommended and conveniently accessible through standard medical practices.
CANCER PREVENTION (PROPHYLACTIC)
For those at high genetic risk of cancer development:
Fenbendazole: 222mg, three times weekly after a fatty meal, followed by a four-day break. Continue this cycle for 10 weeks, then pause for another 10 weeks.
CBD Oil: Apply 25mg under the tongue nightly.
Curcumin: Take 600mg, twice daily with meals.
Milk Thistle: To support liver function, take 250mg twice daily with meals.
This approach aims at an ongoing regimen for cancer deterrence.
Source Article:
FENBENDAZOLE and CANCER at least 12 Anti-Cancer mechanisms of action. Not approved by FDA. Cheap. Safe. Kills aggressive cancers. Why no Clinical Trials? Nine research papers reviewed.
“Ivermectin is FDA approved. Fenbendazole is NOT approved for human use by Food and Drug Administration (FDA) and European Medicines Agency (EMA). It is available as a veterinary medication. Fenbendazole is part of a larger group of drugs known as benzimidazoles, which are anthelmintic drugs (i.e., drugs that kill parasitic worms). Another benzimidazole is mebendazole, which can be prescribed to humans with certain parasitic infections. Mebendazole (Vermox) is FDA approved for human use, but it’s signi cantly more expensive.”
- Dr. William Makis MD
He also quoted the Joe Tippens Cancer Protocol:
Fenbendazole: 222mg per day with food (originally 3 days on, 4 days off)
CBD Oil: Apply 25mg under the tongue daily
Curcumin: Take 600mg per day.
Vitamin E: 800IU per day
Fenbendazole Studies:
2023 Jun - Movahedi et al
Repurposing anti-parasite benzimidazole drugs as selective anti-cancer chemotherapeutics
http://anser.press/index.php/ci/article/view/443/486
2023 Apr - Chi-Son Chang et al
Anti-cancer e ect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancer
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482585/
2023 Mar - Semkova et al
Redox-mediated Anticancer Activity of Anti-parasitic Drug Fenbendazole in Triple-negative Breast Cancer Cells
https://ar.iiarjournals.org/content/43/3/1207.abstract
2023 Mar - Haebeen Jung et al
Di erential cytotoxic e ects of fenbendazole on mouse lymphoma EL-4 cells and spleen cells
https://www.kjvr.org/journal/view.php?number=3907
2022 Sep - Deokbae Park et al
Anti-cancer e ects of fenbendazole on 5-uorouracil resistant colorectal cancer cells
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437363/
2022 Jan - Li-wen Ren et al
Benzimidazoles induce concurrent apoptosis and pyroptosis of human glioblastoma cells via arresting cell cycle
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724275/
2020 Aug - Deok-Soo Son et al
The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458798/
2020 Jun - Yong Han et al
Involvement of reactive oxygen species in the anti-cancer activity of fenbendazole, a benzimidazole anthelmintic (leukemia)
https://www.kjvr.org/journal/view.php?doi=10.14405/kjvr.2020.60.2.79
2018 Aug - Dogra et al
Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways